Comparative Real-World Analysis of Baseline Demographic Characteristics and Comorbidities in Atopic Dermatitis Patients Initiating Biologics Versus JAK Inhibitors
Journal of Clinical Medicine,
Год журнала:
2025,
Номер
14(4), С. 1291 - 1291
Опубликована: Фев. 15, 2025
Background:
Systemic
advanced
therapies,
including
biologic
drugs
and
Janus
kinase
(JAK)
inhibitors,
have
revolutionized
atopic
dermatitis
management.
The
increasing
number
of
available
options
for
such
complex
diseases
demands
careful
treatment
selection
each
patient,
considering
numerous
variables.
Comparative
analyses
these
modalities
in
the
real
world
are
still
limited.
Only
a
faithful
basal
characterization
would
enable
posterior
meaningful
accurate
comparisons
efficacy
safety
profiles
groups
drugs.
This
communication
focuses
on
describing
comparing
baseline
demographics
comorbidities
patients
with
currently
treated
therapies
versus
JAK
inhibitors
our
setting.
Methods:
We
conducted
an
observational,
descriptive,
ambispective
study
across
three
hospitals
covering
population
over
500,000
inhabitants
from
January
2019
to
December
2024.
Baseline
demographic
data,
anthropometric
measures,
lifestyle
factors,
cardiovascular
risk
were
analyzed
using
descriptive
inferential
statistics.
Additionally,
severity
effectivity
time
also
been
compared.
Results:
A
total
150
analyzed.
102
had
received
biological
(dupilumab
or
tralokinumab),
whereas
48
(upadacitinib,
baricitinib,
abrocitinib).
Ages
ranged
11
76
years.
overall
cohort
mean
age
35.87
±
14.37
years
male
predominance
(male-to-female
ratio
1.63:1).
Hypertension
was
more
prevalent
group
(p
=
0.0175),
yet
other
body
measurements,
non-atopic
comorbidities,
disease
comparable
both
groups.
Conclusions:
helped
characterize
characteristics
systemic
real-world
clinical
It
pointed
just
slight
differences
between
biologics
inhibitors.
homogeneity
sets
ground
further
future
outcomes
this
as
potential
confounding
factors
related
imbalances
minimized.
Язык: Английский
Systemtherapie der AD
hautnah dermatologie,
Год журнала:
2025,
Номер
41(S1), С. 6 - 15
Опубликована: Фев. 1, 2025
Dupilumab treatment decreases expression of microRNAs related to B cell activation in peripheral blood mononuclear cells of atopic dermatitis patients
Journal of Dermatological Science,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 1, 2025
Язык: Английский
Risk of infantile atopic dermatitis in neonatal lupus erythematosus: a retrospective cohort study
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Март 27, 2025
Objectives
The
onset
and
progression
of
atopic
dermatitis
(AD)
are
closely
linked
to
autoimmune
status.
While
AD
has
been
observed
in
children
with
neonatal
lupus
erythematosus
(NLE),
its
relationship
perinatal
factors
remains
unclear.
This
study
aimed
identify
early-life
risk
for
the
development
NLE
within
their
first
two
years
life.
Methods
We
conducted
a
multicenter,
retrospective
cohort
using
electronic
medical
records
follow-up
data
from
patients
cohort.
Children
were
categorized
into
non-AD
groups
based
on
whether
they
developed
by
age
two.
Univariate
multivariate
analyses
performed
compare
general
clinical
between
groups.
Results
incidence
was
27.27
(21/77).
Compared
group,
group
had
significantly
lower
use
oral
probiotics
intravenous
gamma
globulin,
but
higher
rates
small-for-gestational-age
(SGA)
status,
hypocomplementemia,
thrombocytopenia,
anti-SSA,
anti-SSB,
double
antibody
(anti-SSA,
anti-SSB)
positivity,
antibiotic
use,
systemic
glucocorticoid
(GC)
treatment.
Logistic
regression
analysis
revealed
that
protective
factor
against
AD,
while
positivity
GC
factors.
Conclusion
In
NLE,
associated
reduced
administration
increased
However,
limited
sample
size
this
warrants
further
findings.
Язык: Английский
Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results
Journal of the European Academy of Dermatology and Venereology,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 3, 2025
Limited
data
exist
on
the
comparative
risk
of
infections
during
biologic
and
Janus
kinase
inhibitor
(JAKi)
treatment
for
atopic
dermatitis
(AD)
in
daily
practice.
To
assess
differential
infection
JAKi
patients
with
moderate-to-severe
AD
a
real-world
setting.
This
prospective,
multicentre
study
evaluated
treatment-emergent
(age
≥
12
years)
using
biologics
or
from
BioDay
registry
October
2017
to
July
2024.
Crude
incidence
rates
were
calculated
per
100
patient-years
(PY)
treatment.
Cox
regression
recurrent
events,
adjusted
potential
confounders,
was
used
estimate
hazard
ratios
(HR)
rate
infections,
subgroup
sensitivity
analyses
bio-/JAKi-naïve
patients.
In
total
1793
included
(4044.1
PY;
1886
episodes
(TEs);
480
JAKi),
794
infections.
showed
higher
(58.4-65.5/100
PY)
compared
(13.6-22.0),
especially
herpes
(n
=
195,
24.6%;
13.6-19.8
vs.
biologicals
3.0-3.6).
indicated
increased
(abrocitinib
HR
4.1,
95%
CI:
3.1-5.5;
baricitinib
4.2,
2.9-6.2;
upadacitinib
4.0,
3.2-5.0;
all
p
<
0.0001)
slight
increase
tralokinumab
(HR
1.4,
1.0-2.0,
0.039)
dupilumab.
Sensitivity
confirmed
these
results,
except
tralokinumab.
Rates
severe
dupilumab,
although
absolute
numbers
low
associations
not
consistently
significant.
History
infection,
predominantly
viral
fungal
skin
1.9,
1.4-2.6,
0.0001;
2.4,
1.3-4.4,
0.003,
resp.),
identified
as
an
independent
factor
associated
infection.
cohort
demonstrated
dupilumab
AD.
These
findings
enhance
understanding
targeted
therapies
AD,
aiding
tailored
choices
that
consider
patient-specific
risks
such
prior
Язык: Английский
Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience
The Journal of Dermatology,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 16, 2025
ABSTRACT
The
JAK/STAT
pathway
is
implicated
in
the
pathogenesis
of
cutaneous
T‐cell
lymphoma
(CTCL),
with
early
studies
suggesting
that
JAK
inhibitors
(JAKi)
may
be
used
for
treating
CTCL.
Patients
CTCL
have
other
indications
JAKi
use,
but
data
on
agents
limited
due
to
warnings
against
their
use
malignancy.
We
retrospectively
characterized
experience
our
tertiary
cancer
center
patients
seen
between
years
2011
and
2024.
identified
26
who
received
a
JAKi:
7
prior
diagnosis
(topical
(
n
=
5)
or
oral
2)
itchy
rash
eczema),
6
as
treatment,
13
following
(oral
ruxolitinib
graft
versus
host
disease
(GvHD)
allogeneic
stem
cell
transplant
9),
hemophagocytic
lymphohistiocytosis
3),
topical
alopecia
areata
1)).
Of
six
treated
JAKi,
four
two
ruxolitinib.
One
patient
orally
has
had
complete
response
3
another
diminishing
lesion
size
1
year.
topically
skin‐limited
demonstrated
plaque
thinning.
nine
GvHD,
five
experienced
relapse
median
8
weeks
exposure.
This
study
provides
initial
insights
into
real‐world
Further
studies,
however,
are
required
characterize
any
association
development,
well
safety
context
pre‐existing
Язык: Английский
Allergic rhinitis and keratoconus: a systematic review and meta-analysis
The Journal of Allergy and Clinical Immunology In Practice,
Год журнала:
2024,
Номер
12(11), С. 3096 - 3104
Опубликована: Июнь 6, 2024
Язык: Английский
Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population‐based cohort study
Allergy,
Год журнала:
2024,
Номер
79(10), С. 2748 - 2758
Опубликована: Авг. 21, 2024
Abstract
Background
Dupilumab
is
the
first
and
only
biologic
agent
approved
for
treatment
of
atopic
dermatitis
(AD)
in
pediatric
patients
aged
from
6
months
to
17
years.
The
study
aimed
evaluate
impact
dupilumab
on
occurrence
comorbidities
with
AD.
Methods
In
this
population‐based
cohort
study,
we
utilized
electronic
health
records
multiple
healthcare
organizations
across
United
States.
Pediatric
(<18
years
age)
a
diagnosis
AD
initiating
were
propensity‐score
matched
1:1
those
other
systemic
agents
(azathioprine,
cyclosporine,
methotrexate,
mycophenolate
mofetil,
or
corticosteroids).
primary
outcomes
new‐onset
emerging
during
period
measured
by
risk
ratio
(RR)
its
confidence
interval
(CI).
Subgroup
analyses
stratified
age
(0–5
years,
6–11
12–17
years),
sex,
race.
Results
A
total
3575
treated
agents.
was
associated
lowered
(including
asthma
[RR,
0.72;
95%
CI,
0.59–0.89]
allergic
rhinitis
0.62;
0.52–0.74]),
infections
(e.g.,
skin
soft
tissue
infection
0.70;
0.63–0.76]
respiratory
tract
[RR
=
0.56;
0.51–0.61]),
psychiatric
disorders
mood
disorder
0.52;
0.39–0.70]
anxiety
0.57;
0.46–0.70],
sleep
disturbance
0.60;
0.47–0.77]),
neurologic
developmental
attention
deficit
hyperactivity
0.54;
0.38–0.75]).
Furthermore,
positive
effects
are
found
be
more
pronounced
younger
children
(aged
0–5
years)
Conclusions
Treatment
compared
resulted
reductions
AD‐related
patients.
Язык: Английский